Ohio is currently home to 3201 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam
NCT02880163
Recruiting
The purpose of this study is to demonstrate safety, effectiveness and benefit-risk profile of ResQFoam for the inhospital treatment of exsanguinating, intraabdominal haemorrhage due to trauma in patients where emergent laparotomy is required.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
07/01/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Hemorrhagic Shock, Trauma, Exsanguinating Hemorrhage, Shock; Traumatic
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Cleveland Clinic Akron General, Akron, Ohio
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
NCT05948475
Recruiting
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Cholangiocarcinoma
Register for Updates
A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection
NCT04706923
Recruiting
The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed once weekly (QW) for 4 weeks in subjects with AdV, and IV BCV in subjects with CMV
Gender:
ALL
Ages:
2 months and above
Trial Updated:
06/20/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Adenovirus Infections, Cytomegalovirus Infection
Register for Updates
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06095583
Recruiting
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy. Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Toledo Clinic Cancer Center - Toledo, Toledo, Ohio
Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC)
Register for Updates
Promoting Caregiver Implementation of an Effective Early Learning Intervention
NCT06275815
Recruiting
The goal of this study is to examine the impact of a caregiver-implemented shared reading program, Sit Together and Read (STAR), on children ages 4 to 5 with developmental language disorder. The main questions it aims to answer are: * how much STAR impacts children's literacy skills in the short-term and long-term--up to two-years after completing STAR. * how do caregiver supports in the form of small monetary rewards or encouraging texts help caregivers to implement STAR at its intended freque... Read More
Gender:
ALL
Ages:
Between 48 months and 71 months
Trial Updated:
06/18/2024
Locations: Schoenbaum Family Center; Crane Center for Early Childhood Research and Policy, Columbus, Ohio
Conditions: Developmental Language Disorder, Reading; Difficult
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, Cincinnati, Ohio
Conditions: Neoplasms
Register for Updates
A Post-Market Domestic (US) and International Data Collection to Assess the Truliant Knee System
NCT05653102
Recruiting
A Post-Market Domestic (US) and International Data Collection to Assess the Truliant® Knee System
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Crystal Clinic, Akron, Ohio
Conditions: Knee Arthroplasty, Total
Register for Updates
Expanded Indications in the Pediatric BONEBRIDGE Population
NCT05615649
Recruiting
This study will assess safety and efficacy of the MED-EL BONEBRIDGE Bone Conduction Implant in children under 12 years old with conductive or mixed hearing loss.
Gender:
ALL
Ages:
Between 3 years and 12 years
Trial Updated:
06/17/2024
Locations: The Ohio State University/Nationwide Children's Hospital, Columbus, Ohio
Conditions: Hearing Loss, Conductive, Hearing Loss, Mixed
Register for Updates
Regulating Together in Tuberous Sclerosis Complex
NCT06105736
Recruiting
The purpose of this study is to use a program called Regulating Together (RT), a remote, non-pharmacologic intervention to treat symptoms of emotion dysregulation in children and adolescents with Tuberous Sclerosis Complex (TSC) and TSC-Associated Neuropsychiatric Disorder (TAND).
Gender:
ALL
Ages:
Between 8 years and 17 years
Trial Updated:
06/07/2024
Locations: Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, Ohio
Conditions: TSC, Behavioral Symptoms
Register for Updates
Creating a Healthy L.I.F.E: Lifestyle Interventions For Epilepsy
NCT05283200
Recruiting
A prospective controlled, randomized study to examine the effects of behavioral and wellness-based interventions on seizure frequency for adult patients with medication resistant epilepsy who are still experiencing 1 or more seizures per month.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/07/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Lifestyle
Register for Updates
Low Voltage-Directed Catheter Ablation for Atrial Fibrillation
NCT03355456
Recruiting
A two-pronged approach to evaluate long term success of non-paroxysmal ablation when using a: 1. specified low voltage-directed with pulmonary vein isolation (LD+PVI) approach compared to , 2. an approach of pulmonary vein isolation (PVI) alone.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/07/2024
Locations: MetroHealth Medical Center, Cleveland, Ohio
Conditions: Atrial Fibrillation - Symptomatic
Register for Updates